|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings显示文摘 | Jameson Forster Ivan Damjanov Zhiyue Lin Irene Sarosiek Paul Wetzel Richard W. McCallum | 2005 | Journal of Gastrointestinal Surgery2005，，1： | 2 |
| 2 | The prognostic value of nailfold capillary changes for the development of connective tissue disease in children and adolescents with primary raynaud phenomenon:A Follow- up Study of 250 Patients显示文摘 | Pavlov-Dolijanovi c S Damjanov N Ostoji c P | 2006 | Pediatr dermatol2006，23，5： | 1 |
| 3 | Dialysis asarisk factor for deveiopment of athero sclerosis显示文摘 | Damjanovic T Dimkovic N | 2003 | Medpregl2003，56，： | 1 |
| 4 | Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical stud-ies显示文摘 | Damjanov N Kauffman RS Spencer-Green GT | 2009 | Arthritis Rheum2009，60，5： | 1 |
| 5 | 显示文摘 | Setter N Damjanovic D Eng L | 2006 | J Appl Phys2006，100，5： | 1 |
| 6 | Using GIS and remote sensing to enhance air navigation safety 显示文摘 | DAMJANOVIC D | 2003 | Photogrammetric Engineering and Remote Sensing2003，69，： | 1 |
| 7 | Animal models of depression显示文摘 | Damjanovic A Petrovic M Vukovic T | 2000 | Vojnosanit Pregl2000，57，6： | 1 |
| 8 | Lead free piezoelectric materials显示文摘 | DEMARTIN M M DAMJANOVIC D SETTER N | 2004 | J Electroceram2004，13，123： | 1 |
| 9 | 微量抗原制备抗体及微量简便筛选抗体的方法显示文摘 | 王荣福 曹蔚文 Andrea Damjanov Ivan Damjanov | 1989 | 中国免疫学杂志1989，，03： | 1 |
| 10 | Retrospective re- view of 331 consecutive immediate single-stage implant recon- structions with acellular dermal matrix: indications, complica- tions, trends, and costs 显示文摘 | Colwell AS Damjanovic B Zahedi B | 2011 | Plast Reconstr Surg2011，128，6： | 1 |
| 11 | Keratin 7 is a marker for a subset of trophoblastic cells in human germ cell tumors 显示文摘 | Damjanov I Osborn M Miettinen M | 1990 | Arch Pathol Lab Med1990，114，1： | 1 |
| 12 | Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings显示文摘 | Forster J Damjanov I Lin Z | | 0，，01： | 1 |
| 13 | Absence of the interstitial cells of cajal in patients with gastroparesis and correlation with clinical findings显示文摘 | Forster J Damjanov I Lin Z | 2005 | J Gastrointest Surg2005，9，1： | 1 |
| 14 | Contributions to the Piezoelctric Effect in Ferroelectric Single Grystals and Ceramics 显示文摘 | Damjanovic D | 2005 | J Am Ceram Soc2005，88，10： | 1 |
| 15 | The protective role of pregnane X receptor in lipopolysaccharide/D-galactosamine-induced acute liver injury显示文摘 | Wang K Damjanov I Wan YJ | 2010 | Lab Invest2010，90，： | 1 |
| 16 | Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud's phenomenon显示文摘 | Pavlov-Dolijanovic S Damjanov NS Stojanovic RM | 2012 | Rheumatol Int2012，32，10： | 1 |
| 17 | Improved materials for environmental application:surfactant-modified zeolites显示文摘 | Jovanovic V Dondur V Damjanovic Lj | 2006 | Materials Science Forum2006，518，： | 1 |
| 18 | Organ distribu- tion of transgene expression following intranasal mucosal delivery of recombinant replication-defeclive adenovirus gene transfer vector 显示文摘 | DAMJANOVIC D ZHANG X MT J | 2008 | Genet Vaccines Ther2008，6，： | 1 |
| 19 | Absence of the interstitial ceils of Cajal in patients with gastroparesis and correlation with clinical findings 显示文摘 | Forster J Damjanov 1 Lin Z | 2005 | J Gastrointest Surg2005，9，1： | 1 |
| 20 | Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma显示文摘Tumor biopsies may help to reliably distinguish hepatocellular carcinoma(HCC) from other tumors, mostly cholangiocarcinoma as well as to identify the patient populations who most benefit from target-driven HCC treatments, in order to improve the success rate of experimental therapies. Clarifying tumor biology may also lead to identify biomarkers with prognostic role and/or enabling to predict response or resistance to therapies. Recently, clinical trials have more efficiently included biomarker endpoints and increasingly collected tumor tissue from enrolled patients. Due to their frail status and sometimes fast-progressing disease, the performance status of patients with HCC progressing on first-line therapy can deteriorate quickly, preventing their enrollment in clinical trials. However, the challenge of identifying the proper patient at the proper time can be overcome by periodic inter-department meetings involving the key specialists taking care of HCC patients, and solid networks between research centers and referring institutions. An early planned biopsy would also facilitate timely inclusion of patients in biology-driven clinical trials. Ultimately, institution of multidisciplinary teams can optimize treatment choice, biopsy timing, and quick enrollment of patients in clinical trials, before their performance status deteriorates. | Lorenza Rimassa Maria Reig Giovanni Abbadessa Markus Peck-Radosavljevic William Harris Vittorina Zagonel Davide Pastorelli Elena Rota Caremoli Camillo Porta Nevena Damjanov Hitendra Patel Bruno Daniele Maria Lamar Brian Schwartz Terri Goldberg Armando Santoro Jordi Bruix | 2017 | World Journal of Gastroenterology2017，23，13： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员